PMID- 37165991
OWN - NLM
STAT- MEDLINE
DCOM- 20230512
LR  - 20230512
IS  - 0022-9040 (Print)
IS  - 0022-9040 (Linking)
VI  - 63
IP  - 4
DP  - 2023 May 1
TI  - [Anthra-cycline-Induced Cardiotoxicity: the Role of Genetic Predictors].
PG  - 22-28
LID - 10.18087/cardio.2023.4.n1946 [doi]
AB  - Aim      To evaluate the predictive significance of gene polymorphism in 
      endothelin-1 type 2A receptor, NADPH oxidase, p53 protein, endothelial nitric 
      oxide synthase, caspase 8, interleukin-1beta, tumor necrosis factor-alpha, superoxide 
      dismutase-2, glutathione peroxidase-1, beta1-adrenoceptor, angiotensin-converting 
      enzyme, and matrix metalloproteinase-3 (MMP-3) genes in evaluating the risk of 
      anthracycline-induced cardiotoxicity (AIC) in women without concurrent 
      cardiovascular diseases (CVD).Material and methods  This study included 176 women 
      aged 45.0 [42.0; 50.0] years with breast cancer without concurrent CVD who were 
      scheduled for polychemotherapy (PCT) with anthracycline antibiotics. 
      Echocardiography was performed for all patients at baseline and at 12 months 
      after the end of PCT course. Genetic polymorphism was determined with the 
      polymerase chain reaction.Results At 12 months, all patients were in remission of 
      the underlying disease. They were retrospectively included into 2 groups: 1st 
      group, 52 patients with AIC and 2nd group, 124 women without AIC symptoms. The 
      development of AIC was associated with the presence of the p53 protein gene 
      Arg / Arg genotype (odds ratio (OR), 2.972; p=0.001), NOS3 gene T / T genotype 
      (OR, 3.059; p=0.018), NADPH oxidase gene T / T genotype (OR, 2.753; p=0.008), 
      GPX1 gene C / C genotype (OR, 2.345; p=0.007), MMP-3 gene 5A / 5A genotype (OR, 
      2.753; p=0.008), and ADRB1 gene G / G genotype (OR, 3.271; 
      p=0.043).Conclusion      Evaluation of genetic polymorphism in p53 protein 
      (rs1042522), NOS3 (rs1799983), NADPH-oxidase (rs4673), GPX1 (rs1050450), ADRB1 
      (Arg389Gly, rs1801253), and MMP-3 (rs3025058) genes can be recommended for use 
      prior to starting chemotherapy in women with breast cancer without CVD for 
      assessing the risk of AIC. A maximum risk of cardiotoxicity is associated with 
      the presence of the p53 protein gene Arg / Arg genotype and NOS3 gene T / T 
      genotype.
FAU - Kopeva, K V
AU  - Kopeva KV
AD  - Research Institute of Cardiology, Tomsk National Research Medical Center.
FAU - Grakova, E V
AU  - Grakova EV
AD  - Research Institute of Cardiology, Tomsk National Research Medical Center.
FAU - Shilov, S N
AU  - Shilov SN
AD  - Novosibirsk State Medical University.
FAU - Popova, A A
AU  - Popova AA
AD  - Novosibirsk State Medical University.
FAU - Berezikova, E N
AU  - Berezikova EN
AD  - Novosibirsk State Medical University, Novosibirsk.
FAU - Neupokoeva, M N
AU  - Neupokoeva MN
AD  - Novosibirsk State Medical University.
FAU - Ratushnyak, E T
AU  - Ratushnyak ET
AD  - Novosibirsk State Medical University.
FAU - Teplyakov, A T
AU  - Teplyakov AT
AD  - Research Institute of Cardiology, Tomsk National Research Medical Center.
LA  - rus
PT  - English Abstract
PT  - Journal Article
DEP - 20230501
PL  - Russia (Federation)
TA  - Kardiologiia
JT  - Kardiologiia
JID - 0376351
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - 0 (Anthracyclines)
RN  - EC 1.6.3.- (NADPH Oxidases)
SB  - IM
MH  - Humans
MH  - Female
MH  - Tumor Suppressor Protein p53/genetics
MH  - Matrix Metalloproteinase 3/genetics
MH  - Retrospective Studies
MH  - Cardiotoxicity/etiology
MH  - Genotype
MH  - Nitric Oxide Synthase Type III/genetics
MH  - *Cardiovascular Diseases/genetics
MH  - *Breast Neoplasms
MH  - Anthracyclines
MH  - NADPH Oxidases/genetics
MH  - Genetic Predisposition to Disease
MH  - Polymorphism, Single Nucleotide
EDAT- 2023/05/11 13:18
MHDA- 2023/05/12 07:06
CRDT- 2023/05/11 06:33
PHST- 2021/11/23 00:00 [received]
PHST- 2022/03/25 00:00 [accepted]
PHST- 2023/05/12 07:06 [medline]
PHST- 2023/05/11 13:18 [pubmed]
PHST- 2023/05/11 06:33 [entrez]
AID - 10.18087/cardio.2023.4.n1946 [doi]
PST - epublish
SO  - Kardiologiia. 2023 May 1;63(4):22-28. doi: 10.18087/cardio.2023.4.n1946.